Aim:Trolox, a direct scavenger of peroxyl and alkoxyl radicals, is known to have antioxidant effects. Neuroblastoma (NB) is the second leading extracranial solid tumor of early childhood, with approximately two-thirds of cases occurring before the age of 5 years and accounting for approximately 15 percent of all pediatric cancer deaths. Treatments against NB are inadequate, resulting in a low survival rate in high-risk patients. This study was conducted to determine the effects of the anticancer dose of Trolox on cytotoxic, oxidant, antioxidant, and cytokine levels in the neuroblastoma cancer line (SH-SY5Y cell line). Material and Methods:In cell culture, SH-SY5Y cells were grown in an appropriate nutrient medium and under appropriate conditions. Five different doses of Trolox (50, 100, 200, 400, and 800 μM) were applied to the cell line for 24 and 48 hours. Analysis of Trolox applications was performed by MTT cytotoxicity tests, total oxidant and total antioxidant tests, and pro-inflammatory cytokine tests. Results:According to the data obtained, the application of 200 μM Trolox reduced cancer cell viability by up to 77.76%. Trolox exhibited a dose-dependent effect on the SH-SY5Y cell line. In addition, it was determined that 200 μM Trolox reduced oxidant activity, increased antioxidant capacity, and decreased pro-inflammatory cytokine levels in neuroblastoma cells, consistent with the cytotoxicity test. Conclusion:As a result, it was seen that 200 μM Trolox had an anticancer effect on the neuroblastoma cell line.